Comprehensive commissioning and quality assurance validation of EthosTM therapy

Purpose. - Adaptive radiotherapy with the Ethos((R)) therapy Varian system has been recently implementedat the Montpellier Cancer Institute, France. This article details the commissioning performed before the implementation of this new treatment planning system (TPS). Material and methods. - To validate the golden beam data of the machine (Halcyon linear accelerator), percentage depth doses (PDD) and profiles were measured for several field sizes and at different depths with a microdiamond chamber. The final doses calculated for different plan types with the Ethos Acuros XB algorithm and the Halcyon Eclipse Analytic Anisotropic Algorithm were compared using the gamma index method. Lastly, for the patient quality assurance (QA) process, the patient treatment plan results obtained with the Mobius3D QA platform (Varian) were compared with the portal dosimetry results obtained with Epiqa (Epidos). Results. - Minor differences were observed for the PDD and profile curves (mean difference of 0.2% and 2%, respectively). The chi index pass rate was above 98% for all measures using the 1%/1 mm and 2%/2 mm criteria for PDD and profile evaluations. The Ethos AXB algorithm was validated for every configuration( fixed fields, standard IMRT and VMAT fields, and clinical plans) with 2D/3D gamma index values > 99%. Seventy-three 3-arcs-VMAT QA plans and 27 9-fields-IMRT QA plans were evaluated. Both showed excellent agreement with the TPS calculations (mean gamma pass rate higher than 99%). No difference was observed between IMRT and VMAT. Conclusion. - The beam delivery, the Ethos AXB algorithm, and the patient QA were comprehensively validated using independent tools. (c) 2023 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. Allrights reserved.